Post-Marketing Safety Surveillance Should Include Data Mining Techniques, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The advantages and limitations of data analysis from large adverse event databases are described in a draft guidance. Safety signals found through data mining should be put in the context of total patients exposed to the drug and considered for further investigation, FDA recommends.